Interestingly, of the most frequently mutated genes in PCa, only TP53 showed higher mutation rate in the NEPC high-risk group compared to the low-risk group in both PRAD and CRPC/Met cohorts, while higher mutation rates of AR and RB1 were observed only in the NEPC high-risk group in SU2C CRPC/Met dataset (Figure S6C-D). This evidence concerns the gene AR and prostate adenocarcinoma.